1. Home
  2. HIW vs CPRX Comparison

HIW vs CPRX Comparison

Compare HIW & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HIW

Highwoods Properties Inc.

HOLD

Current Price

$33.13

Market Cap

3.5B

Sector

Real Estate

ML Signal

HOLD

Logo Catalyst Pharmaceuticals Inc.

CPRX

Catalyst Pharmaceuticals Inc.

HOLD

Current Price

$31.49

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIW
CPRX
Founded
1978
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.9B
IPO Year
1995
2006

Fundamental Metrics

Financial Performance
Metric
HIW
CPRX
Price
$33.13
$31.49
Analyst Decision
Hold
Strong Buy
Analyst Count
7
1
Target Price
$27.57
$35.00
AVG Volume (30 Days)
2.0M
2.0M
Earning Date
04-28-2026
05-11-2026
Dividend Yield
8.43%
N/A
EPS Growth
54.26
28.24
EPS
0.29
0.50
Revenue
$806,112,000.00
$119,072,803.00
Revenue This Year
$6.03
$9.20
Revenue Next Year
$3.58
$10.51
P/E Ratio
$115.07
$62.98
Revenue Growth
N/A
16.39
52 Week Low
$20.45
$19.05
52 Week High
$33.47
$32.56

Technical Indicators

Market Signals
Indicator
HIW
CPRX
Relative Strength Index (RSI) 73.66 70.31
Support Level $25.13 $31.25
Resistance Level N/A $32.56
Average True Range (ATR) 0.76 0.04
MACD 0.08 -0.05
Stochastic Oscillator 85.19 86.96

Price Performance

Historical Comparison
HIW
CPRX

About HIW Highwoods Properties Inc.

Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Share on Social Networks: